NASDAQ · Biotechnology · USD

Boundless Bio, Inc. (BOLD) Stock Analysis

Boundless Bio, Inc. (BOLD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BOLD

$2.44

+$0.01 (+0.41%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BOLD with… →

BOLD Key Statistics

As of Oct 21, 2026

Trading

Open: $2.53
Previous Close: $2.43
Day's Range: 2.41–2.57
52-Week Range: 0.96–3.16
Volume: 64.26K
Beta: 0.47

Valuation

Market Cap: $53.38M
P/E Ratio: unprofitable
EPS (ttm): −2.85

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$58.20M
Shares Outstanding: 23.11M
1-Year Return: +63.76%

Dividend and dates

Avg Volume: 186.96K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BOLD closed at $2.44, +63.76% over 1 year.

Boundless Bio, Inc. (BOLD) has a market capitalization of $53.38M.

In fiscal 2025, BOLD reported revenue of $0.00.

BOLD Stock Return by Calendar Year

Boundless Bio, Inc. (BOLD) return since Mar 2024: what $10,000 became

1 year: $10,000 $16,376; +63.76%
Since Mar 2024: $10,000 $1,712; −82.88%

If you had invested $10,000 in Boundless Bio, Inc. (BOLD) at the close on March 28, 2024, the earliest close on record here, it would have been worth $1,712 at the close on October 21, 2026: −82.88% in total, −49.74% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−79.65%−58.62%+103.33%

2024*20252026*

Year	Return
2026 (partial year)	+103.33%
2025	−58.62%
2024 (partial year)	−79.65%

As of October 21, 2026.

BOLD Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$58.20M	—
2024	$0.00	−$65.36M	—
2023	$0.00	−$49.43M	—
2022	$0.00	−$45.90M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$63.55M	−$58.20M	—
2024	$0.00	—	−$73.27M	−$65.36M	—
2023	$0.00	—	−$54.80M	−$49.43M	—
2022	$0.00	—	−$46.47M	−$45.90M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

The market values Boundless Bio, Inc. (BOLD) at $53.38M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 28.

BOLD last closed at $2.44 on October 21, 2026. That is +$0.01 (+0.41%) against the previous close. Over the past 52 weeks the price has ranged from $0.96 to $3.16. The latest close sits 153.9% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $58.20M. Earnings per share on a trailing basis come to −2.85.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is +63.76%. The stored price history starts on March 28, 2024, and the total return since then is −82.88%. The reported beta is 0.47. Daily returns over the trailing 2 years annualize to a volatility of 86.85%.

Growth & Income

The record shows no dividend for BOLD.

2026 is still running; the total return is +103.33% year to date. The record holds one complete calendar year, 2025, which returned −58.62%.

Peer Comparison

Boundless Bio, Inc. (BOLD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Boundless Bio, Inc.	BOLD	$53.38M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Boundless Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Boundless Bio, Inc.

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Visit website →